These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30227048)

  • 1. Breakthrough Therapy Designation: CDER Analysis of Requests 4 Years Into the Program.
    Conrad R; Taylor K; Raggio M; Harrington A; Stark G; Kish A; Bertha A
    Ther Innov Regul Sci; 2017 Jul; 51(4):509-515. PubMed ID: 30227048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decisions on Non-oncology Breakthrough Therapy Designation Requests in 2017-2019.
    Poddar A; Raggio M; Concato J
    Ther Innov Regul Sci; 2024 Jan; 58(1):214-221. PubMed ID: 37926768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations.
    Daizadeh I
    Ther Innov Regul Sci; 2019 Mar; 53(2):264-269. PubMed ID: 29874936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations.
    Hanaizi Z; Kweder S; Thor S; Ribeiro S; Marcal A
    Ther Innov Regul Sci; 2023 Mar; 57(2):321-328. PubMed ID: 36307671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An FDA Analysis of Formal Dispute Resolution in the Center for Drug Evaluation and Research: 2003 Through 2014.
    Sharma K; Harrington A; Worrell S; Bertha A
    Ther Innov Regul Sci; 2016 Nov; 50(6):697-704. PubMed ID: 30231744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breakthrough Therapy Designation: Bringing Innovation Swiftly to Patients.
    Shah A
    Ther Innov Regul Sci; 2015 Mar; 49(2):256-261. PubMed ID: 30222423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development Speed.
    Pregelj L; Hine DC; Kesselheim AS; Darrow JJ
    Clin Pharmacol Ther; 2021 Oct; 110(4):1018-1024. PubMed ID: 34048058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the breakthrough-therapy-designated drugs granted in China: A pooled analysis 2020-2022.
    Luo X; Qian F; Yang L; Li Y; Yang Y
    Drug Discov Today; 2022 Dec; 27(12):103370. PubMed ID: 36154876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Expedited Programs in the United States on Oncology Drug Development in Japan.
    Tanaka M; Matsumaru N; Tsukamoto K
    Ther Innov Regul Sci; 2019 Mar; 53(2):199-206. PubMed ID: 29732928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.
    Hwang TJ; Franklin JM; Chen CT; Lauffenburger JC; Gyawali B; Kesselheim AS; Darrow JJ
    J Clin Oncol; 2018 Jun; 36(18):1805-1812. PubMed ID: 29688832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing standards for breakthrough therapy designation in oncology.
    Horning SJ; Haber DA; Selig WK; Ivy SP; Roberts SA; Allen JD; Sigal EV; Sawyers CL
    Clin Cancer Res; 2013 Aug; 19(16):4297-304. PubMed ID: 23719260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology.
    Kern KA
    J Oncol Pract; 2016 Aug; 12(8):e810-7. PubMed ID: 27460496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacists' Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation.
    Herink MC; Johnston K; Breninger K; Wu E; Irwin AN
    Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician Perceptions of the FDA's Breakthrough Therapy Designation: An Update.
    Paquin RS; Boudewyns V; O'Donoghue AC; Aikin KJ
    Oncologist; 2022 Feb; 27(1):e85-e88. PubMed ID: 35305103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA's Role in Ensuring Patient Safety.
    Jarow JP; Lemery S; Bugin K; Lowy N
    Ther Innov Regul Sci; 2017 Mar; 51(2):246-249. PubMed ID: 28553566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breakthrough therapy-designated oncology drugs: are they rightfully criticized?
    Mulder J; Pasmooij AMG; Stoyanova-Beninska VV; Schellens JHM
    Drug Discov Today; 2020 Sep; 25(9):1580-1584. PubMed ID: 32562841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals.
    Herink MC; Irwin AN; Zumach GM
    Pharmacotherapy; 2018 Sep; 38(9):967-980. PubMed ID: 30043413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA's Expedited Programs and Their Impact on the Availability of New Therapies.
    Damle N; Shah S; Nagraj P; Tabrizi P; Rodriguez GE; Bhambri R
    Ther Innov Regul Sci; 2017 Jan; 51(1):24-28. PubMed ID: 30235999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.